Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

References

• Igel M, von Sudhop T, Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002; 42:835–451Igel M, von Sudhop T, Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002; 42:835–45
   PubMed Web of Science ®Google Scholar
• Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4:117–382Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4:117–38
   PubMedGoogle Scholar
• Hull CK, Penman AD, Smith CK. et al. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772:219–283Hull CK, Penman AD, Smith CK. et al. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772:219–28
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–414Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
   PubMed Web of Science ®Google Scholar
• Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users’ Guide-Part V: Introductory Guide. NONMEM Project Group C255 University of California at San Francisco. Regents of the University of California, 1991.5Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users’ Guide-Part V: Introductory Guide. NONMEM Project Group C255 University of California at San Francisco. Regents of the University of California, 1991.
   Google Scholar
• Cooper KJ, Martin PD, Dane AL. et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51–66Cooper KJ, Martin PD, Dane AL. et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51–6
   PubMed Web of Science ®Google Scholar
• White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963–707White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963–70
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL. et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822–358Martin PD, Warwick MJ, Dane AL. et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822–35
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL. et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25:2553–639Martin PD, Warwick MJ, Dane AL. et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25:2553–63
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA. et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75:455–6310Schneck DW, Birmingham BK, Zalikowski JA. et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75:455–63
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL. et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322–911Cooper KJ, Martin PD, Dane AL. et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322–9
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL. et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003;55:94–912Cooper KJ, Martin PD, Dane AL. et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003;55:94–9
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL. et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527–3113Cooper KJ, Martin PD, Dane AL. et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527–31
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Nwose OM. et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42: 1116–2114Martin PD, Dane AL, Nwose OM. et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42: 1116–21
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL. et al. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003;25:2215–2415Martin PD, Warwick MJ, Dane AL. et al. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003;25:2215–24
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Schneck DW. et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459–7116Martin PD, Dane AL, Schneck DW. et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459–71
   PubMed Web of Science ®Google Scholar
• Sekino H, Onishi T. Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor-evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J Clin Ther Med 2005; 21:187–20317Sekino H, Onishi T. Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor-evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J Clin Ther Med 2005; 21:187–203
   Google Scholar
• Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472–718Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472–7
   PubMed Web of Science ®Google Scholar
• Warwick MJ, Dane AL, Raza A. et al. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [abstract]. Atherosclerosis 2000;151:3919Warwick MJ, Dane AL, Raza A. et al. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [abstract]. Atherosclerosis 2000;151:39
   Google Scholar
• Lee E, Ryan S, Birmingham B. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78:330–4120Lee E, Ryan S, Birmingham B. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78:330–41
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD. et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167–7721Simonson SG, Raza A, Martin PD. et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167–77
   PubMed Web of Science ®Google Scholar
• Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410–1422Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410–14
   PubMed Web of Science ®Google Scholar